What matters for you? 

A 10 minute scoping survey for women  | A 10 minute scoping survey for health professionals: 

An international collaboration between the European Society of Human Reproduction and Embryology (ESHRE), American Society of Reproductive Medicine (ASRM), International Menopause Society (IMS) and Centre of Research Excellence- Women's Health in Reproductive Life (CRE-WHiRL) are partnering to update the 2016 ESHRE POI guideline. 

Survey - for women

We invite you to take part in this research about the content, resources and tools for the new POI guideline and share your opinions as a woman with POI/ Premature menopause.

https://tinyurl.com/2p9ynpce

Survey - for health professionals

We invite you to take part in this research about the content, resources and tools for the new POI guideline and share your opinions as a health professional caring for woman with POI/ Premature menopause.

https://tinyurl.com/yc4kr566

The product Happy Hormones is a listed medicine with the Therapeutics Goods Administration (TGA) but it's effectiveness has not been assessed in clinical trials. The AMS supports clinical research to determine the safety and efficacy of all products used in the treatment of menopausal symptoms.

A Phase II randomised double-blind, placebo-controlled clinical trial evaluating the efficacy of Happy Hormones in menopausal women

Study description

This phase II double-blind, placebo controlled randomised clinical trial aims to assess the effectiveness of a herbal formula for women experiencing menopausal symptoms. Involvement will include participation in a randomized placebo-controlled clinical trial, which means participants will receive either a placebo or an active product for 12 weeks. A placebo is a treatment which is designed to have no therapeutic value, but is similar in look, taste and smell to the other treatment being tested. It is an online telehealth trial, so is open to women from anywhere in Australia and you will not be required to visit a trial site. Participants are required to fill out questionnaires online or via post every 4 weeks, and keep a daily log of their well-being, in addition they are required to visit a pathology lab at the beginning and end of the study for getting their blood tested for liver and kidney function.

NCNM Clinical Trial Flyer Happy Hormones1.81 MB

Inclusion criteria

We are seeking generally healthy menopausal women aged between 40 and 66 years who experience three or more vasomotor symptoms (hot flushes) within a 24-hour period. Participants need to have a body weight index (BMI) between 18-30 kg/m2 (will be extended to 35 kg/m2) and have normal liver and kidney function. Women who take hormone therapy, or hormone replacement therapy cannot be considered.

Ethics approval

Southern Cross University HREC No: 2021/036

HH HREC Application Approval Notification 2021-4-19129.95 KB

Study location

Australia-wide

More Information about the trial: https://redcap.link/ood4lh3s 

About the study: 

We are assessing therapy to prevent bone loss and restore sexual function in women with primary ovarian insufficiency. 

This is a 12-month study using topical testosterone cream applied to the skin on women aged under 45 years with primary ovarian insufficiency (complete loss of ovarian function before age 40).

Your participation will involve 5 visits with blood collection and bone density scans.

Researchers 

Women’s Health Research Program, Monash University

Ethics Approval

This study is approved by Monash University Human Research  Ethics Committee

Contact

To participate or for further information
Please contact:
Women’s Health Research Program
Monash University
Phone: (03) 99030827
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
The Women’s Health Research Program

POI_Study_Flyer_v3_20_Oct_2021133.97 KB

[Ref:

[V3 dated 20.07.2021]

About the study: 

We are recruiting women across Australia who are under the age of 45 and are at high risk for ovarian cancer and planning a bilateral salpingo-oopherectamy (BSO) within the next 12 months, as well as women under the age of 45 who have undergone BSO in the past 12 months. 

This project is conducted via videoconferencing (all online) and involves interviews to assess mood and cognition.  

Lead researchers 

Associate Professor Caroline Gurvich (Clinical Neuropsychologist, Monash University)

Associate Professor Amanda Vincent (Endocrinologist, Monash Health and Monash University) 

Professor Martha Hickey (Professor of Obstetrics and Gynaecology, RWH and University of Melbourne).  

Ethics Approval

This research has approval from ethics committee (Alfred Health Ethics Committee and Monash University ethics committee) and is funded by The Centre for Research Excellence in Women's Health in Reproductive Life (CRE WHiRL) and the Women's Health Research Translation Network (WHRTN). 

Contact

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Phone: 03 9076 5034

 

If you or your loved one are above the age of 40 and experiencing the following symptoms, you may be eligible to participate in a clinical trial investigating a potential new medication for perimenopausal women with depression:

Depressive symptoms:

• Feeling down or low all of the time
• Fatigue or lacking energy
• Thoughts of helplessness or worthlessness
• Change in appetite
• Trouble sleeping
• Difficulties in concentration
• Loss of interest in activities that were once enjoyable

Perimenopausal symptoms:

• Irregular periods more than 60 days apart but less than 365 days apart
• 4 or more hot flushes per day/night

If you are interested, please get in touch with one of our friendly research teams. Contact details of our lead doctors are as given below.

Study: Depressed with Perimenopausal Symptoms?587.47 KB

Meet the lead doctors: 

---

Epworth Clinic

Professor Paul Fitzgerald

Site Name: Epworth Centre for Innovation in Mental Health (ECIMH)

Address: 888 Toorak Road, Camberwell, VIC, 3124

Phone: (03) 9805 4363

Email: This email address is being protected from spambots. You need JavaScript enabled to view it. OR This email address is being protected from spambots. You need JavaScript enabled to view it. 

---

NeuroCentrix

Dr Peter Farnbach

Site Name: NeuroCentrix

Address: 1303 Heatherton Rd, Noble Park 3174

Phone: (03) 9546 0009

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.  

---

Monash University

Professor Jayashri Kulkarni

Site Name: MAPrc / Alfred Health

Address: Level 4, 607 St Kilda Road Melbourne, Victoria 3004

Phone: +61 3 9076 6564

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

COMMA (Core Outcome Set for Menopausal Symptoms) is inviting clinicians, researchers and women who have experienced menopause around the world to provide input on what symptoms should be measured in trials of treatments for menopausal symptoms. Clinical trials for menopausal symptoms have measured a wide range of different outcomes, making it difficult to compare treatments and limiting the relevance of these studies for clinical practice. COMMA will standardise this process by developing a “Core Outcome Set” of measures for future clinical trials.

Please complete this short survey to tell us what menopausal symptoms you believe are most important.  These responses will be used to develop a new Core Outcome Set reflecting the views of clinicians and consumers. Please also circulate the survey amongst your networks

COMMA is funded by the University of Melbourne and supported by menopause societies internationally and the leading journals in menopause.

The survey takes about 10 minutes and all those who complete the survey will be included in a draw for a $200 Westfield voucher.

The survey is now closed.

Originally published May 2019

Content updated January 2021

Description of Study

MonaLisa Touch^TM (MLT) is a new treatment for women with vulvovaginal symptoms that involves treatment of the vaginal lining with tiny pin-point laser applications with the aim of restoring the skin to a state similar to that prior to the menopause. At present, there is not enough evidence about the effectiveness of MonaLisa Touch^TM for it to be recommended as a medical treatment. It is currently expensive to access and there is no Medicare rebate available.

Researchers are currently running a clinical trial in Australia which will evaluate how effective MonaLisa Touch^TM is in treating postmenopausal vulvovaginal symptoms and provide high quality information to guide women with vulvovaginal symptoms as to their best treatment options.

Recruitment has now closed, and results will be available later in 2020.

For more information, please contact the GRACE Research group at the Royal Hospital for Women in Sydney:

Ethics Approval 

Department of Gynaecology, Royal Hospital for Women HREC ref no: 15/330

Investigator

Prof Jason Abbott

Contact details

This email address is being protected from spambots. You need JavaScript enabled to view it.

Phone 0491 231 771

Note: This page is only available for viewing by registered members. Study pages, when accepted, will be available to the public.